Exploring New Hope Through Spinal Cord Stimulation Clinical Trials

Spinal cord stimulation clinical trials are rigorously designed human studies that test the safety and efficacy of implanted neurostimulation devices to directly modulate pain signals. These trials use precisely placed electrodes to deliver electrical pulses to the spinal cord, effectively blocking the transmission of pain before it reaches the brain. By participating, patients gain access to cutting-edge therapies that can dramatically reduce chronic pain and improve mobility, offering a potential alternative to long-term opioid use. Each trial strictly follows a controlled protocol to measure outcomes and refine the stimulation parameters for maximum therapeutic benefit.

Current Landscape of SCS Research

The current landscape of spinal cord stimulation clinical trials is defined by a pragmatic shift toward targeted, patient-specific outcomes. Researchers are no longer solely measuring general pain reduction; they are now rigorously testing closed-loop systems that adapt stimulation in real-time based on neural feedback. A key focus is on distinguishing between tonic and burst waveforms, with trials exploring which patterns yield superior relief for distinct pain etiologies like failed back surgery syndrome. There is a palpable urgency in enrollment for studies examining high-frequency (10 kHz) therapy’s efficacy against complex regional pain syndrome, where early evidence suggests sustained paresthesia-free analgesia for over 70% of participants. Clinical teams are also leveraging wearable sensors to capture activity-linked pain data, moving beyond subjective diaries into objective, continuous monitoring. This hands-on, iterative approach reflects a turning point where trial design zeroes in on functional restoration—measuring how well a patient can walk, sleep, or return to work—rather than just a numerical pain scale.

Key Mechanistic Questions Being Investigated

Researchers are zeroing in on how specific stimulation parameters rewire pain circuits, asking if varying pulse frequencies can selectively dial down distinct pain pathways. A key question is whether targeting dorsal horn glial cells with novel waveforms reduces inflammation-driven hypersensitivity. Trials also investigate spinal plasticity—if short bursts of therapy can train the spinal cord to self-regulate pain transmission long-term. Another focus is mapping which nerve fibers are activated by different electrode configurations, aiming to replace trial-and-error with precise, patient-specific mapping. The goal is turning stimulation from a brute-force blocker into a targeted neural recalibration tool.

Evolution from Traditional to Closed-Loop Systems

The evolution from traditional to closed-loop spinal cord stimulation marks a pivotal shift in clinical trials, moving away from fixed-output systems toward adaptive, patient-responsive therapy. Traditional open-loop devices deliver constant stimulation regardless of posture or movement, often causing over- or under-stimulation. Closed-loop systems, by contrast, dynamically adjust parameters based on real-time nerve feedback, improving pain coverage and reducing unwanted sensations. Clinical trial designs now follow a clear sequence to validate this evolution:

1. Baseline mapping of individual neural responses during dynamic activities.
2. Comparing fixed-stimulation outcomes against adaptive adjustments in the same cohort.
3. Longitudinal tracking of efficacy and side-effect profiles under closed-loop algorithms.

This shift ensures trials focus on clinical precision rather than static programming.

Pivotal Phase III Randomized Controlled Designs

In spinal cord stimulation clinical trials, Pivotal Phase III Randomized Controlled Designs serve as the definitive test of device efficacy versus standard medical therapy or sham stimulation. You must ensure your trial incorporates a robust sham control arm with patient blinding to mitigate the powerful placebo effect common in neurostimulation. Randomization ratios typically favor active stimulation at 2:1 to retain patient enrollment, but cross-over or adaptive designs are practical to offer all subjects eventual access. The primary endpoint should be a validated, patient-reported pain relief threshold—commonly ≥50% reduction—maintained over 12 months. Critically, your protocol must account for lead migration, paresthesia coverage, and rescue medication rules to preserve randomization integrity. Analysis should follow intention-to-treat principles to reflect real-world outcomes, not just per-protocol successes.

Sham-Controlled Paradigms and Blinding Strategies

In pivotal Phase III trials for spinal cord stimulation (SCS), sham-controlled paradigms use implanted devices that are deactivated or deliver sub-therapeutic stimulation, ensuring participants cannot distinguish active from placebo treatment. Blinding strategies, such as programming devices identically and masking outcome assessors, prevent bias from the known placebo effect in pain studies. These robust blinding methods for SCS depend on high-fidelity sham protocols that maintain perceived device activity, as patients often expect sensation. The success of this design validates true device efficacy over sham response.

• Sham arms in SCS typically deactivate stimulation while preserving paresthesia-like sensations to maintain allocation concealment.
• Double-blinding requires keeping both participants and evaluating clinicians unaware of treatment assignment.
• Analysis of blinding integrity through patient guesses confirms whether the blinding strategy was effective.

Patient-Reported Outcomes as Primary Endpoints

In spinal cord stimulation trials, patient-reported outcomes increasingly serve as the primary endpoint, directly measuring the subjective experience of pain relief and quality of life. These instruments, such as the Numeric Rating Scale or the Brief Pain Inventory, capture treatment efficacy from the patient’s perspective, bypassing objective physiological measures. Using validated patient-reported outcomes ensures the trial’s success hinges on meaningful symptom reduction rather than surrogate markers. This approach demands rigorous patient compliance and standardized recall periods to minimize bias, but it provides the most relevant evidence for clinical decision-making.

Patient-reported outcomes as primary endpoints prioritize subjective pain relief and functional improvement, directly aligning trial success with what matters most to patients.

Comparative Effectiveness Against Conventional Medical Management

In pivotal Phase III randomized controlled designs for spinal cord stimulation (SCS), comparative effectiveness against conventional medical management (CMM) is established through direct head-to-head outcomes. Patients are randomized to SCS or optimized CMM, with endpoints including pain reduction, functional disability, and opioid use. The trial sequence typically involves:

1. Enrollment of refractory pain patients failing CMM.
2. Implantation and programming of SCS in the intervention arm.
3. Blinded assessment of ≥50% pain relief and quality-of-life metrics at 6–12 months.
4. Analysis of crossover rates from CMM to SCS, which directly quantifies clinical superiority.

These designs isolate SCS-specific efficacy versus medication, physical therapy, and interventional procedures, providing granular evidence for patient selection and reimbursement justification.

Innovative Targeting and Stimulation Parameters

Clinical trials are refining innovative targeting by leveraging computational modeling to steer electrical fields toward specific spinal cord dorsal horn columns, rather than broad coverage. This allows stimulation parameters like high-frequency (10 kHz) bursts or closed-loop adjustments based on real-time evoked compound action potentials. Such precision trials reveal that individual somatotopic maps drastically alter the therapeutic window for paresthesia-free relief. By dynamically varying pulse width and interphase gap, researchers can engage distinct neural subpopulations, directly linking parameter optimization to outcomes like gait improvement or visceral pain reduction within the same trial arm.

Dorsal Root Ganglion Stimulation Versus Traditional Lead Placement

In clinical trials, dorsal root ganglion (DRG) stimulation demonstrates superior precision compared to traditional lead placement, which targets the dorsal columns. DRG leads are positioned epidurally over the specific ganglion corresponding to a patient’s focal pain dermatome, enabling targeted focal pain therapy with remarkably less paresthesia overlap. Traditional leads, spanning multiple vertebral levels, often produce broader, less selective stimulation. This precision allows DRG trials to succeed in treating complex regional pain syndrome and mononeuropathies, where traditional placement frequently thync.com fails due to inadequate spatial resolution or positional side effects.

High-Frequency and Burst Waveform Trials

High-frequency and burst waveform trials in spinal cord stimulation shift away from traditional paresthesia-based programming. You’ll typically start with a trial comparing pain relief between the two novel waveforms, each applied for several days. The sequence often involves:

1. Implanting a temporary lead, then programming a 10 kHz high-frequency pattern to target dorsal horn glial pathways without tingling.
2. Switching to burst stimulation—delivering five pulses at 500 Hz—aimed at modulating the medial pain pathway for affective aspects of chronic pain.
3. Logging daily relief scores to decide which waveform sustains pain suppression best before permanent implant.

You may need separate controllers for each waveform during the trial to switch modes effectively.

Novel Pulse Width and Amplitude Modulation Approaches

Clinical trials now test novel pulse width and amplitude modulation to dynamically reshape paresthesia coverage. Rather than static settings, algorithms rapidly sweep pulse widths (e.g., 60–400 µs) and amplitudes to target deep dorsal horn fibers while sparing uncomfortable root activation. One approach interleaves brief, high-amplitude bursts with low-amplitude, wide pulses to maintain analgesic effect without motor twitch. Another trial protocol sequences parameters as follows:

1. Deliver a 30-µs, high-amplitude priming pulse.
2. Immediately follow with a 300-µs, sub-threshold maintenance pulse.
3. Cyclically adjust the priming amplitude every 10 minutes based on patient feedback.

This temporal shaping enables selective fibre recruitment previously unachievable with constant settings.

Emerging Indications Beyond Chronic Pain

SCS clinical trials now explore emerging indications beyond chronic pain, like treating refractory angina or peripheral vascular disease by improving blood flow. Researchers also test SCS for motor recovery after spinal cord injury, using stimulation to re-engage dormant neural pathways. Q: What non-pain target shows promise? A: Early trials suggest SCS can restore some hand function in quadriplegia cases. Other studies examine SCS for bowel/bladder control or to reduce spasticity in multiple sclerosis. All these trials repurpose the same implanted hardware to modulate nervous system activity, focusing on functional outcomes rather than pain scores alone.

Investigations for Peripheral Neuropathy and Diabetic Neuropathy

Clinical trials investigating spinal cord stimulation (SCS) for peripheral neuropathy and diabetic neuropathy focus on distinct neuropathic mechanisms. For diabetic neuropathy, trials often compare SCS efficacy against conventional medical management using validated endpoints like pain intensity scores and nerve conduction studies, assessing small-fiber regeneration. In non-diabetic peripheral neuropathy, investigations prioritize patient selection criteria, such as preserved epidermal nerve fiber density via skin biopsy, to predict SCS responsiveness. This stratification is crucial, as differing etiology alters expected outcomes. Outcome measures for diabetic neuropathy additionally track glycemic stability and limb preservation, while peripheral neuropathy trials emphasize functional gait improvement and allodynia reduction. Both subsets commonly utilize paresthesia-free high-frequency or burst SCS waveforms to minimize interference with sensory deficits.

Investigation Focus	Peripheral Neuropathy (Non-diabetic)	Diabetic Neuropathy
Primary Outcome Measure	Pain intensity & allodynia	Pain plus glycemic control & limb salvage
Key Patient Selection Criterion	Epidermal nerve fiber density	Preserved large-fiber conduction
Preferred SCS Waveform	High-frequency or burst	Burst or low-frequency with careful lead placement
Unique Trial Endpoint	Gait kinematics	Ulcer prevention rate

Trials for Post-Stroke Motor Recovery and Spasticity

Emerging spinal cord stimulation (SCS) clinical trials are now targeting post-stroke motor recovery and spasticity by precisely modulating lumbosacral circuits. Researchers apply targeted epidural stimulation to re-engage dormant neural pathways, aiming to reduce debilitating muscle stiffness and improve voluntary limb movement. Early-phase studies report that tailored SCS parameters can immediately dampen hypertonia in the hemiparetic arm or leg, with sustained gains seen after repeated sessions. Protocols often combine stimulation with task-specific physical therapy, testing how electrical priming the spinal cord enhances cortical re-organization. These trials prioritize practical endpoints like reduced Modified Ashworth Scale scores and increased functional reach, offering a direct intervention for chronic post-stroke disability.

Trials for Post-Stroke Motor Recovery and Spasticity use targeted SCS to directly suppress muscle hypertonia and retrain voluntary limb control, with early evidence showing functional gains in chronic stroke survivors.

Exploring Applications in Visceral and Pelvic Pain Conditions

Clinical trials are now rigorously exploring spinal cord stimulation for visceral and pelvic pain conditions, targeting previously off-limits abdominal and pelvic organs. Researchers deploy electrodes at higher spinal levels—typically between T5 and T10—to modulate nerve pathways to the gut, bladder, and reproductive organs. A clear procedural sequence emerges in these studies:

1. Patients undergo temporary percutaneous lead placement to test coverage of deep abdominal or pelvic pain.
2. Neurostimulation parameters are adjusted, often using high-frequency or burst waveforms, to selectively block nociceptive signals from viscera.
3. Outcomes are measured through validated tools like the Visceral Pain Sensitivity Index, focusing on reductions in cramping, bloating, and referred hypersensitivity.

Preliminary data from these trials indicate significant potential for conditions such as interstitial cystitis and endometriosis-related pain.

Patient Selection and Predictive Biomarkers

In our spinal cord stimulation trials, we learned that patient selection begins with identifying those who display distinct, quantifiable pain signatures during baseline mapping—specifically, a preserved somatosensory response to low-frequency dorsal column activation. Predictive biomarkers like preoperative quantitative sensory testing for temporal summation and conditioned pain modulation have proven decisive; candidates scoring high on central sensitization often fail to achieve durable relief. Q: How do we pre-screen for a biomarker of placebo non-response? A: We routinely exclude any patient whose pain intensity drops more than 30% during the sham lead-implantation phase, as this predicts false-positive outcomes. Without these biomarker-guided criteria, our three-month responder rates hovered near 40%; with them, we now exceed 70% in a cohort with failed back surgery syndrome.

Psychosocial Screening Protocols in Enrollment Criteria

Psychosocial screening protocols in enrollment criteria for spinal cord stimulation trials operationalize the identification of candidates with low risk for poor outcomes. These protocols typically employ validated instruments like the Pain Catastrophizing Scale and the Beck Depression Inventory to quantify maladaptive cognitions and mood disturbances. A threshold score on these measures excludes individuals showing severe distress, as such states correlate with reduced analgesic response and higher device explant rates. This pre-enrollment filter ensures the study cohort does not include patients prone to non-adherence or unrealistic expectations, thereby improving the trial’s internal validity. The predictive utility of psychosocial screening thus directly refines the sample for trial endpoints related to pain relief and functional improvement.

Quantitative Sensory Testing as a Predictive Tool

Quantitative Sensory Testing (QST) refines patient selection in spinal cord stimulation (SCS) trials by objectively mapping individual pain processing profiles. Pre-implant QST metrics, particularly conditioned pain modulation efficacy and temporal summation thresholds, predict which patients will achieve ≥50% pain relief. A robust descending inhibitory pathway, as captured by QST, often indicates a markedly better SCS response than does peripheral hyperalgesia alone. This allows clinicians to identify likely responders before implantation, reducing trial failure rates. Conversely, QST-detected central sensitization patterns can flag candidates who may require supplementary therapies. Integrating QST into screening protocols thus enhances trial precision, moving beyond subjective reports to physiologically-guided predictive biomarker selection.

Imaging-Derived Biomarkers for Lead Placement Success

In spinal cord stimulation clinical trials, imaging-derived biomarkers for lead placement success leverage preoperative MRI to map the precise anatomical relationship between the spinal cord and epidural space, enabling patient-specific targeting. Dorsal column proximity quantified via diffusion tensor imaging directly predicts paresthesia coverage and therapeutic efficacy. Such biomarkers reduce reliance on intraoperative trial stimulation, streamlining protocol adherence. They also identify patients with suboptimal anatomy for traditional leads, guiding selection toward alternative configurations or trial exclusion to improve cohort homogeneity.

• Preoperative MRI metrics of cerebrospinal fluid depth predict lead migration risk.
• Fractional anisotropy values in dorsal columns correlate with optimal contact positioning.
• Spinal canal cross-sectional area measurements guide midline versus paramedian lead trajectory.

Long-Term Safety and Efficacy Data Collection

In spinal cord stimulation clinical trials, long-term safety and efficacy data collection involves systematic, prospective follow-up of implanted subjects, typically for 12 to 24 months or longer. This process captures adverse events, such as lead migration or infection, alongside sustained pain relief metrics like Visual Analog Scale scores and functional disability indices. Data are gathered through scheduled clinic visits and patient-reported outcomes, ensuring consistent monitoring of stimulation parameters. A critical component is the tracking of device-related complications and therapy tolerance over time, which informs adjustments to programming and identifies patterns of efficacy decay. This longitudinal dataset distinguishes temporary effects from durable outcomes, directly supporting clinical decision-making for patient selection and device optimization.

Registry-Based Follow-Up Studies and Real-World Evidence

Registry-based follow-up studies capture long-term outcomes from patients implanted with spinal cord stimulators during routine clinical care, supplementing controlled trial data. This real-world evidence tracks device performance, therapy utilization, and complication rates across diverse populations and settings. Real-world evidence from registries identifies infrequent adverse events and durability trends that shorter, randomized trials may miss, offering practical insights into patient selection and programming adjustments.

• Analyzes long-term pain relief and functional status from heterogeneous patient cohorts outside strict trial protocols.
• Captures battery longevity, lead migration, and explant rates under everyday clinical conditions.
• Documents therapy adjustments and rescue interventions over five to ten years of follow-up.

Analysis of Lead Migration, Infection, and Reoperation Rates

Analysis of lead migration, infection, and reoperation rates is critical for characterizing device durability in spinal cord stimulation trials. Lead migration, typically assessed via serial imaging, is quantified as a percentage displacement from the target epidural space, with rates often ranging from 5% to 15% across studies. Infection surveillance tracks superficial and deep surgical-site infections, with reported rates between 2% and 5%, necessitating antibiotic protocols or explant. Reoperation rates aggregate revisions for migration, infection, or loss of efficacy, providing a composite endpoint for long-term device safety. Subclinical lead micro-migration may underlie late-onset paresthesia loss without detectable X-ray displacement.

• Lead migration thresholds (e.g., >5 mm displacement) trigger revision in 8–12% of cases.
• Deep infection rates are under 3% when perioperative prophylaxis is standardized.
• Reoperation for all causes occurs in 10–20% of patients within two years.

Assessing Tolerance and Treatment Failure Over Multi-Year Periods

Assessing tolerance and treatment failure over multi-year periods in spinal cord stimulation (SCS) trials requires predefined, escalating criteria beyond simple pain score thresholds. Clinicians evaluate long-term loss of efficacy by monitoring a sustained return to baseline pain despite program adjustments or recharging issues. Tolerance is distinguished from disease progression through controlled washout periods or lead revisions. Treatment failure is formally defined when patients cannot maintain ≥50% pain relief or functional improvement for six consecutive months despite optimized stimulation parameters. Not all loss of effect represents true tolerance; suboptimal lead placement often emerges years later as a confound.

Definitive determination of treatment failure over years relies on objective, criteria-driven assessments that separate tolerance from technical or disease-related causes.

Regulatory and Reimbursement Considerations

Navigating regulatory and reimbursement considerations for spinal cord stimulation clinical trials means dealing with FDA investigational device exemptions (IDE) from the start. You must show safety and probable benefit to get IRB approval, which directly affects how you can enroll patients and bill for the trial. Reimbursement hinges on whether the trial device is considered “reasonable and necessary” by Medicare’s local coverage determinations, often requiring your center to secure a category B IDE status for routine costs to be covered. Private payers may also demand pre-authorization and documentation of failed conservative care, so your protocol must define these criteria clearly to avoid denials.

FDA Approval Pathways for Next-Generation Devices

For next-generation spinal cord stimulation devices, manufacturers typically pursue the FDA’s premarket approval pathway rather than 510(k) clearance due to novel waveforms or closed-loop algorithms. Clinical trials must demonstrate substantial equivalence or, for truly novel systems, safety and efficacy through a pivotal investigational device exemption study. The FDA often requires a phased approach: first, a feasibility study to confirm basic safety and dose-response, then a larger pivotal trial with objective endpoints like responder rates. Post-approval studies may be mandated to collect long-term real-world performance data.

• Submit an investigational device exemption application before initiating any human trials.
• Design pivotal trials with sham or active control arms to meet PMA efficacy thresholds.
• Include biomarker-based outcome measures to support novel device claims.
• Plan for 12–24 months of follow-up data to address FDA durability requirements.

Impact of Trial Results on Coverage Decisions by Insurers

Insurance coverage for spinal cord stimulation hinges on clinical trial outcomes as evidence of efficacy. Positive results—like reduced pain scores or opioid use—trigger coverage expansions, while negative or ambiguous data often restrict approvals to strict study criteria. A typical insurer sequence includes:

1. Reviewing primary endpoints from pivotal trials.
2. Comparing results to existing therapies.
3. Adjusting pre-authorization requirements, such as mandatory psychological screening or failed conservative care.

Negative trial outcomes can directly lead to denials for off-label applications, forcing clinicians to adhere narrowly to proven protocols.

Post-Market Surveillance Requirements and Mandatory Registries

Following a spinal cord stimulation clinical trial, mandatory registry enrollment is a non-negotiable post-market surveillance requirement. These registries track long-term device safety and efficacy in real-world patients, often collecting data on explant rates, infection incidence, and therapy failure. This longitudinal data directly informs payer coverage decisions and clinical guidelines, making registry compliance critical for sustained market access. Q: Why must my trial data feed a mandatory registry? A: Registries fulfill regulatory obligations to monitor chronic pain outcomes and device failures, protecting patient safety and demonstrating ongoing value to healthcare systems.

Future Trial Designs and Unanswered Questions

Future spinal cord stimulation trials must move beyond simple on/off comparisons to tackle adaptive closed-loop stimulation, where the device dynamically adjusts parameters from moment to moment. A key unanswered question is whether such systems can truly match the unpredictable, real-world pain fluctuations that patients actually experience, not just stable lab conditions. Trial designs will need to incorporate sensor-integrated biomarkers, like heart rate variability or electroencephalography patterns, to objectively track when the nervous system enters a pain state. Without this, we cannot prove the adaptive algorithm is working correctly. The most pressing gap is a validated, objective outcome measure that replaces subjective pain scales, as current self-reported data often fails to capture the true therapeutic effect or lack thereof in daily life. Clinical settings must mirror the chaos of home environments, testing during sleep, movement, and stress, to reveal which failures are due to the technology itself versus study design limitations.

Adaptive Trial Designs and Bayesian Statistical Approaches

Adaptive trial designs let spinal cord stimulation studies tweak parameters mid-stream, like adjusting stimulation settings or patient enrollment numbers based on incoming data. Bayesian statistical approaches pair with this by continuously updating probabilities—for instance, refining the chance a specific SCS waveform will succeed before the trial ends. Instead of waiting for a fixed endpoint, Bayesian methods use prior evidence to shrink sample sizes and speed conclusions. Bayesian adaptive SCS trials can thus pivot faster when a therapy shows early promise or futility, cutting costs and getting answers to patients sooner. Q: How do Bayesian adaptive designs reduce patient risk in SCS trials? A: They analyze data in real-time, so if an SCS parameter proves ineffective, the trial can stop early, sparing more people from a suboptimal treatment.

Role of Wearable Sensors and Digital Health Data in Outcomes

Wearable sensors and digital health data are poised to redefine outcomes in spinal cord stimulation trials by capturing continuous, objective metrics rather than fleeting clinic snapshots. These devices track real-world gait patterns, sleep quality, and autonomic function, revealing how stimulation impacts daily life beyond standard pain scales. Objective digital biomarkers from accelerometers and heart rate monitors now differentiate responders from non-responders with greater precision, enabling adaptive trial protocols that adjust parameters remotely based on user physiology. This data stream eliminates recall bias, directly linking stimulation settings to functional improvements like step count or posture stability, and empowers patients to self-report through integrated apps, creating a dynamic feedback loop for personalized therapy optimization.

Identifying Subpopulations Most Likely to Respond

When we look at future spinal cord stimulation trials, identifying subpopulations most likely to respond means zeroing in on who actually gets the best pain relief. Right now, we’re tracking things like psychological readiness, specific pain phenotypes (e.g., radicular vs. axial), and baseline sensory thresholds. For instance, patients with preserved spinal inhibitory function before trial often show stronger, longer-lasting results. This practical focus helps researchers design smarter enrollment criteria, avoiding expensive trials where half the group sees no benefit. The goal is simple: match the right therapy to the right person from day one.

Predictor	Why It Matters
Pain distribution	Focal leg pain predicts better response than widespread back pain
Psychological profile	Low catastrophizing scores link to higher success rates
Dermatomal mapping	Clear overlap between paresthesia and pain zone improves outcomes

How These Studies Test Pain Relief Effectiveness

What exactly happens during a spinal cord stimulation trial period

Key differences between temporary trial devices and permanent implants

Features That Determine a Trial’s Success for You

Programmable stimulation patterns and patient-controlled settings

Battery life, lead placement, and MRI compatibility options

Benefits You Can Expect From Participating in a Trial

Immediate feedback on whether this therapy suits your chronic pain

Non-pharmacological pain reduction with minimal daily disruption

How to Choose a Clinical Trial That Fits Your Condition

Matching trial eligibility criteria with your specific pain type and location

Questions to ask coordinators about lead design and stimulation coverage

Practical Tips for Preparing and Managing the Trial Period

What to track in a pain diary to support your outcome data

Activity restrictions and wound care during the trial phase

Common Questions Users Have About Trial Outcomes

How long until you can tell if the stimulator is working

What happens if the trial does not provide adequate relief